74 results on '"Gaspar, Laurie E."'
Search Results
2. An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting
- Author
-
Elhalawani, Hesham, Elgohari, Baher, Lin, Timothy A., Mohamed, Abdallah S.R., Fitzgerald, Thomas J., Laurie, Fran, Ulin, Kenneth, Kalpathy-Cramer, Jayashree, Guerrero, Thomas, Holliday, Emma B., Russo, Gregory, Patel, Abhilasha, Jones, William, Walker, Gary V., Awan, Musaddiq, Choi, Mehee, Dagan, Roi, Mahmoud, Omar, Shapiro, Anna, Kong, Feng-Ming (Spring), Gomez, Daniel, Zeng, Jing, Decker, Roy, Spoelstra, Femke O.B., Gaspar, Laurie E., Kachnic, Lisa A., Thomas, Charles R., Jr., Okunieff, Paul, and Fuller, Clifton D.
- Published
- 2019
- Full Text
- View/download PDF
3. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
- Author
-
Andrews, David W., Scott, Charles B., Sperduto, Paul W., Flanders, Adam E., Gaspar, Laurie E., Schell, Michael C., Werner-Wasik, Maria, Demas, William, Ryu, Janice, Bahary, Jean-Paul, Souhami, Luis, Rotman, Marvin, Mehta, Minesh P., and Curran, Walter J., Jr.
- Subjects
Radiosurgery -- Research ,Cancer -- Care and treatment ,Cancer -- Research ,Clinical trials - Published
- 2004
4. Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?
- Author
-
Sperduto, Paul W., Fang, Penny, Li, Jing, Breen, William, Brown, Paul D., Cagney, Daniel, Aizer, Ayal, Yu, James, Chiang, Veronica, Jain, Supriya, Gaspar, Laurie E., Myrehaug, Sten, Sahgal, Arjun, Braunstein, Steve, Sneed, Penny, Cameron, Brent, Attia, Albert, Molitoris, Jason, Wu, Cheng-Chia, and Wang, Tony J.C.
- Abstract
The literature describing the prognosis of patients with gastrointestinal (GI) cancers and brain metastases (BM) is sparse. Our group previously published a prognostic index, the Graded Prognostic Assessment (GPA) for GI cancer patients with BM, based on 209 patients diagnosed from 1985-2005. The purpose of this analysis is to identify prognostic factors for GI cancer patients with newly diagnosed BM in a larger contemporary cohort. A multi-institutional retrospective IRB-approved database of 792 GI cancer patients with new BM diagnosed from 1/1/2006 to 12/31/2016 was created. Demographic data, clinical parameters, and treatment were correlated with survival and time from primary diagnosis to BM (TPDBM). Kaplan-Meier median survival (MS) estimates were calculated and compared with log-rank tests. The MS from time of first treatment for BM for the prior and current cohorts were 5 and 8 months, respectively (P < 0.001). Eight prognostic factors (age, stage, primary site, resection of primary tumor, Karnofsky Performance Status (KPS), extracranial metastases, number of BM and Hgb were found to be significant for survival, in contrast to only one (KPS) in the prior cohort. In this cohort, the most common primary sites were rectum (24%) and esophagus (23%). Median TPDBM was 22 months. Notably, 37% (267/716) presented with poor prognosis (GPA 0-1.0). Although little improvement in overall survival in this cohort has been achieved in recent decades, survival varies widely and multiple new prognostic factors were identified. Future work will translate these factors into a prognostic index to facilitate clinical decision-making and stratification of future clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Physician Bias in Prophylactic Cranial Irradiation Decision Making-An Opportunity for a Patient Decision Aid.
- Author
-
Robin, Tyler P., Sannes, Timothy S., Feng-Ming Spring Kong, Mornex, Francoise, Hirsch, Fred R., Rusthoven, Chad G., and Gaspar, Laurie E.
- Published
- 2018
- Full Text
- View/download PDF
6. Physician Bias in Prophylactic Cranial Irradiation Decision Making-An Opportunity for a Patient Decision Aid.
- Author
-
Petrelli, Fausto, Maltese, Mariangela, Tomasello, Gianluca, Conti, Barbara, Borgonovo, Karen, Cabiddu, Mary, Ghilardi, Mara, Ghidini, Michele, Passalacqua, Rodolfo, Barni, Sandro, Brighent, Matteo, Robin, Tyler P, Sannes, Timothy S, Spring Kong, Feng-Ming, Mornex, Francoise, Hirsch, Fred R, Rusthoven, Chad G, and Gaspar, Laurie E
- Published
- 2018
- Full Text
- View/download PDF
7. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.
- Author
-
Robin, Tyler P., Camidge, D. Ross, Stuhr, Kelly, Nath, Sameer K., Breeze, Robert E., Pacheco, Jose M., Liu, Arthur K., Gaspar, Laurie E., Purcell, W. Thomas, Doebele, Robert C., Kavanagh, Brian D., Rusthoven, Chad G., and Pacheco, Jose
- Published
- 2018
- Full Text
- View/download PDF
8. American College of Radiology–American Brachytherapy Society practice parameter for electronically generated low-energy radiation sources.
- Author
-
Devlin, Phillip M., Gaspar, Laurie E., Buzurovic, Ivan, Demanes, D. Jeffrey, Kasper, Michael E., Nag, Subir, Ouhib, Zoubir, Petit, Joshua H., Rosenthal, Seth A., Jr.Small, William, Wallner, Paul E., and Hartford, Alan C.
- Subjects
- *
RADIOISOTOPE brachytherapy , *RADIOTHERAPY treatment planning , *BREAST cancer treatment , *SKIN cancer , *RADIOTHERAPY safety - Abstract
Background This collaborative practice parameter technical standard has been created between the American College of Radiology and American Brachytherapy Society to guide the usage of electronically generated low energy radiation sources (ELSs). It refers to the use of electronic X-ray sources with peak voltages up to 120 kVp to deliver therapeutic radiation therapy. Main Findings The parameter provides a guideline for utilizing ELS, including patient selection and consent, treatment planning, and delivery processes. The parameter reviews the published clinical data with regard to ELS results in skin, breast, and other cancers. Conclusions This technical standard recommends appropriate qualifications of the involved personnel. The parameter reviews the technical issues relating to equipment specifications as well as patient and personnel safety. Regarding suggestions for educational programs with regard to this parameter,it is suggested that the training level for clinicians be equivalent to that for other radiation therapies. It also suggests that ELS must be done using the same standards of quality and safety as those in place for other forms of radiation therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Lung Cancer in Patients [is less than] 50 Years of Age
- Author
-
Gadgeel, Shirish M., Ramalingam, Sakkaraiappan, Cummings, Glenn, Kraut, Michael J., Wozniak, Antoinette J., Gaspar, Laurie E., and Kalemkerian, Gregory P.
- Subjects
Lung cancer -- Demographic aspects ,Health ,Demographic aspects - Abstract
The Experience of an Academic Multidisciplinary Program Objective: To determine if the clinicopathologic features and survival of lung cancer patients [is less than] 50 years of age differ from those [...]
- Published
- 1999
10. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.
- Author
-
Jackson, Matthew W., Palma, David A., Camidge, D. Ross, Jones, Bernard L., Robin, Tyler P., Sher, David J., Koshy, Matthew, Kavanagh, Brian D., Gaspar, Laurie E., and Rusthoven, Chad G.
- Published
- 2017
- Full Text
- View/download PDF
11. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies.
- Author
-
Khalifa, Jonathan, Amini, Arya, Popat, Sanjay, Gaspar, Laurie E., Faivre-Finn, Corinne, and International Association for the Study of Lung Cancer Advanced Radiation Technology Committee
- Published
- 2016
- Full Text
- View/download PDF
12. Radiotherapeutic Management of Non-Small Cell Lung Cancer in the Minimal Resource Setting.
- Author
-
Rodin, Danielle, Grover, Surbhi, Xu, Melody J., Hanna, Timothy P., Olson, Robert, John Schreiner, L., Munshi, Anusheel, Mornex, Francoise, Palma, David, Gaspar, Laurie E., Schreiner, L John, and International Association for the Study of Lung Cancer Advanced Radiation Technology Committee
- Published
- 2016
- Full Text
- View/download PDF
13. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
- Author
-
Wozniak, Antoinette J, Moon, James, Thomas Jr, Charles R, Kelly, Karen, Mack, Philip C, Gaspar, Laurie E, Raben, David, Fitzgerald, Thomas J, Pandya, Kishan J, Gandara, David R, and Thomas, Charles R Jr
- Published
- 2015
- Full Text
- View/download PDF
14. Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs.
- Author
-
Compton, Julia J., Gaspar, Laurie E., Shrieve, Dennis C., Wilson, Lynn D., Griem, Katherine L., Amdur, Robert J., and Lee, W. Robert
- Subjects
- *
RADIOISOTOPE brachytherapy , *ONCOLOGY , *RADIATION , *GRADUATE medical education , *REGRESSION analysis , *MEDICAL sciences - Abstract
Abstract: Purpose: To describe resident-reported experience in brachytherapy in Accreditation Council of Graduate Medical Education–accredited radiation oncology training programs over the last 5 years. Methods and Materials: Archived reports of Accreditation Council of Graduate Medical Education final resident case logs from the last 5 years were reviewed and summarized. Brachytherapy was categorized according to the dose rate (low dose rate vs. high dose rate), technique (interstitial vs. intracavitary), and primary tumor site. Linear regression was used to test for trends. Results: The mean number of total brachytherapy procedures performed per resident in the last 5 years has decreased from 80.8 in 2006–2007 to 71.0 in 2010–2011, but the trend is not statistically significant. The average number of intracavitary procedures has remained steady. The average resident experience with interstitial brachytherapy has decreased in a statistically significant manner. The average number of interstitial procedures has decreased by 25%. Conclusions: The average number of interstitial procedures reported by residents has decreased by 25%. The community charged with training residents in interstitial brachytherapy should consider methods to ensure that residents obtain sufficient experience in the future. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
15. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
- Author
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR, Weickhardt, Andrew J, Scheier, Benjamin, Burke, Joseph Malachy, Gan, Gregory, Lu, Xian, Bunn, Paul A Jr, Aisner, Dara L, Gaspar, Laurie E, and Kavanagh, Brian D
- Published
- 2012
- Full Text
- View/download PDF
16. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline.
- Author
-
Tsao, May N., Rades, Dirk, Wirth, Andrew, Lo, Simon S., Danielson, Brita L., Gaspar, Laurie E., Sperduto, Paul W., Vogelbaum, Michael A., Radawski, Jeffrey D., Wang, Jian Z., Gillin, Michael T., Mohideen, Najeeb, Hahn, Carol A., and Chang, Eric L.
- Subjects
TREATMENT of brain cancer ,BRAIN metastasis ,OPERATIVE surgery ,CANCER radiotherapy ,SURGICAL excision ,CANCER prognosis - Abstract
Abstract: Purpose: To systematically review the evidence for the radiotherapeutic and surgical management of patients newly diagnosed with intraparenchymal brain metastases. Methods and Materials: Key clinical questions to be addressed in this evidence-based Guideline were identified. Fully published randomized controlled trials dealing with the management of newly diagnosed intraparenchymal brain metastases were searched systematically and reviewed. The U.S. Preventative Services Task Force levels of evidence were used to classify various options of management. Results: The choice of management in patients with newly diagnosed single or multiple brain metastases depends on estimated prognosis and the aims of treatment (survival, local treated lesion control, distant brain control, neurocognitive preservation). Single brain metastasis and good prognosis (expected survival 3 months or more): For a single brain metastasis larger than 3 to 4 cm and amenable to safe complete resection, whole brain radiotherapy (WBRT) and surgery (level 1) should be considered. Another alternative is surgery and radiosurgery/radiation boost to the resection cavity (level 3). For single metastasis less than 3 to 4 cm, radiosurgery alone or WBRT and radiosurgery or WBRT and surgery (all based on level 1 evidence) should be considered. Another alternative is surgery and radiosurgery or radiation boost to the resection cavity (level 3). For single brain metastasis (less than 3 to 4 cm) that is not resectable or incompletely resected, WBRT and radiosurgery, or radiosurgery alone should be considered (level 1). For nonresectable single brain metastasis (larger than 3 to 4 cm), WBRT should be considered (level 3). Multiple brain metastases and good prognosis (expected survival 3 months or more): For selected patients with multiple brain metastases (all less than 3 to 4 cm), radiosurgery alone, WBRT and radiosurgery, or WBRT alone should be considered, based on level 1 evidence. Safe resection of a brain metastasis or metastases causing significant mass effect and postoperative WBRT may also be considered (level 3). Patients with poor prognosis (expected survival less than 3 months): Patients with either single or multiple brain metastases with poor prognosis should be considered for palliative care with or without WBRT (level 3). It should be recognized, however, that there are limitations in the ability of physicians to accurately predict patient survival. Prognostic systems such as recursive partitioning analysis, and diagnosis-specific graded prognostic assessment may be helpful. Conclusions: Radiotherapeutic intervention (WBRT or radiosurgery) is associated with improved brain control. In selected patients with single brain metastasis, radiosurgery or surgery has been found to improve survival and locally treated metastasis control (compared with WBRT alone). [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
17. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
- Author
-
Amin NP, Miften M, Kavanagh B, Raben D, Camidge DR, Thornton D, Rochford N, Gaspar LE, Amin, Neha P, Miften, Moyed, Kavanagh, Brian, Raben, David, Camidge, D Ross, Thornton, Dale, Rochford, Nicole, and Gaspar, Laurie E
- Published
- 2011
- Full Text
- View/download PDF
18. Successful treatment of radiation-induced optic neuropathy.
- Author
-
Weintraub, Julie A., Bennett, Jeffrey, and Gaspar, Laurie E.
- Subjects
NEUROPATHY ,RADIOTHERAPY ,OPTIC nerve ,DRUG side effects ,LITERATURE reviews ,RADIATION dosimetry - Abstract
Abstract: Radiation-induced optic neuropathy is a rare but devastating side effect after radiation treatment. The treatment options for radiation-induced optic neuropathy have been limited and largely unsuccessful. A review of the literature was conducted to summarize the rationale and possible benefits of various treatments for radiation-induced optic neuropathy. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
19. ACR Appropriateness Criteria® : Single Brain Metastasis.
- Author
-
Suh, John H., Videtic, Gregory M. M., Aref, Amr M., Germano, Isabelle, Goldsmith, Brian J., Imperato, Joseph P., Marcus, Karen J., McDermott, Michael W., McDonald, Mark W., Patchell, Roy A., Robins, H. Ian, Rogers, C. Leland, Wolfson, Aaron H., Wippold II, Franz J., and Gaspar, Laurie E.
- Subjects
METASTASIS ,CANCER genetics ,BRAIN cancer ,RADIOSURGERY ,CANCER invasiveness - Abstract
Single brain metastasis represents a common neurologic complication of cancer. Given the number of treatment options that are available for patients with brain metastasis and the strong opinions that are associated with each option, appropriate treatment for these patients has become controversial. Prognostic factors such as recursive partitioning analysis and graded prognostic assessment can help guide treatment decisions. Surgery, whole brain radiation therapy (WBRT), stereotactic radiosurgery or combination of these treatments con be considered based an a number of factors. Despite Class I evidence suggestive of best therapy, the treatment recommendation is quite varied among physicians as demonstrated by the American College of Radiolagy's Appropriateness Panel an single brain metastasis. Given the potential concerns of the neurocognitive effects of WBRT, the use of SRS alone or SRS to a resection cavity has gained support. Since aggressive local therapy is beneficial for survival, local control and quality of life, the use of these various treatment modalities needs to be carefully investigated given the growing number of long-term survivors. Enrollment of patients onto clinical trials is important to advance our understanding of brain metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
20. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Image-Guided Radiation Therapy (IGRT)
- Author
-
Potters, Louis, Gaspar, Laurie E., Kavanagh, Brian, Galvin, James M., Hartford, Alan C., Hevezi, James M., Kupelian, Patrick A., Mohiden, Najeeb, Samuels, Michael A., Timmerman, Robert, Tripuraneni, Prabhakar, Vlachaki, Maria T., Xing, Lei, and Rosenthal, Seth A.
- Published
- 2010
- Full Text
- View/download PDF
21. American College of Radiology Appropriateness Criteria on Multiple Brain Metastases
- Author
-
Videtic, Gregory M.M., Gaspar, Laurie E., Aref, Amr M., Germano, Isabelle M., Goldsmith, Brian J., Imperato, Joseph P., Marcus, Karen J., McDermott, Michael W., McDonald, Mark W., Patchell, Roy A., Robins, H. Ian, Rogers, C. Leland, Suh, John H., Wolfson, Aaron H., and Wippold, Franz J.
- Published
- 2009
- Full Text
- View/download PDF
22. Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions.
- Author
-
Sangha, Randeep, Lara, Jr., Primo N., Adjei, Alex A., Baas, Paul, Choy, Hak, Gaspar, Laurie E., Goss, Glenwood, Saijo, Nagahiro, Schiller, Joan H., Vokes, Everett E., and Gandara, David R.
- Published
- 2009
- Full Text
- View/download PDF
23. Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
- Author
-
Price, Katharine A.R., Azzoli, Christopher G., and Gaspar, Laurie E.
- Abstract
Patients with unresectable stage III nonsmall cell lung cancer (T4, N3, or bulky N2) live longer if they receive chemotherapy before or concurrent with thoracic irradiation. Randomized clinical trials have shown that concurrent chemoradiation is superior to sequential chemotherapy followed by radiation, with a 20% reduction in the risk of death compared with the sequential approach. However, concurrent chemoradiation is more toxic than the sequential approach, with an increased risk of radiation esophagitis, pneumonitis, and cytopenias, including febrile neutropenia. The phase III trials showing the superiority of the concurrent approach all used cisplatin-based chemotherapy and enrolled patients with a good performance status. For patients who are not eligible for cisplatin, or who have a poor performance status, weight loss, or poor lung function, a sequential approach may be used with full doses of chemotherapy followed by radiation. Another approach currently being studied in phase III trials is to use lower doses of chemotherapy concurrent with radiation followed by full-dose chemotherapy after radiation, so-called concurrent followed by consolidation therapy. Treatment should be planned by the radiation and medical oncologist with careful selection of approach based on the patient''s fitness, comorbid medical illness, and size and location of the tumor. The goal of treatment is to maximize efficacy and minimize toxicity that may interfere with delivery of drug or radiation. In the future, more effective, less toxic chemotherapy drugs and better radiation techniques should improve outcomes for patients with unresectable stage III non-small cell lung cancer (NSCLC). [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
24. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
- Author
-
Einhorn, Lawrence H., Bonomi, Philip, Bunn Jr, Paul A., Camidge, D Ross, Carbone, David Paul, Choy, Hak, Dubinett, Steven M., Gandara, David R., Gaspar, Laurie E., Govindan, Ramaswamy, Johnson, David H., Minna, John D., Scagliotti, Giorgio, West, Howard J., Herbst, Roy S., and Bunn, Paul A Jr
- Published
- 2008
- Full Text
- View/download PDF
25. Patterns of Surgical Care of Lung Cancer Patients.
- Author
-
Little, Alex G., Rusch, Valerie W., Bonner, James A., Gaspar, Laurie E., Green, Mark R., Webb, W. Richard, and Stewart, Andrew K.
- Subjects
LUNG cancer ,ADENOCARCINOMA ,CANCER patients ,LYMPH nodes ,SURGICAL excision - Abstract
Background: This survey was performed to determine the patterns of surgical care provided patients with non-small cell lung carcinoma (NSCLC). Methods: In 2001, the American College of Surgeons carried out a patient care survey of 729 hospitals to retrieve information of NSCLC patients’ history, evaluation, pathology, and surgical treatment. Results: Inclusion criteria were met by 40,090 patients: of whom 11,668 (29.1%) were treated surgically; 74.2% alone and 25.8% as part of multimodality therapy. Of these patients, 59.5% were in stage I, 17.5% in stage II, 17.0% in stage III, and 6.0% in stage IV. Surgery patient demographics were the following: 55% male and 45% female; 46.8% 70 years or older; and 76.3% had significant comorbidities. Tumor characteristics: squamous 28%, adenocarcinoma 37.6%, other 34.4%. Staging: in addition to radiologic examinations, preoperative mediastinoscopy was performed in 27.1% of operated patients with node biopsy in only 46.6% of these procedures. Operations: wedge resection 15.6%, lobectomy 70.8%, pneumonectomy 13.6%. Surgical margins were positive in 7.8%, but only 65.2% had frozen section analysis. Perioperative mortality was 5.2%, but was 4.0% in nontransfused patients and 12.7% in transfused patients and was 3.2% in high-volume (more than 90 operations per year) versus 4.8% in low-volume hospitals (p < 0.001). Conclusions: (1) Patients being operated for NSCLC are elderly with significant comorbid conditions. (2) More patients than previously are female and have adenocarcinoma. (3) Mediastinoscopy is infrequently performed and lymph nodes are biopsied in less than 50% of them. (4) Lobectomy is the most common operation, and positive surgical margins are too frequent. (5) Operative mortality is reasonable but transfusion is a marker for increased risk and outcomes are superior in high-volume hospitals. (6) Hospitals with higher volume had fewer perioperative deaths. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
26. A Gray Zone Regarding Gray Matter.
- Author
-
Gaspar, Laurie E
- Subjects
- *
BRAIN tumors , *LUNG cancer , *LUNG tumors , *RADIOSURGERY , *GRAY matter (Nerve tissue) - Published
- 2019
- Full Text
- View/download PDF
27. MINI01.15: Prophylactic Cranial Irradiation (PCI) for Limited Small Cell Lung Cancer (LSCLC): An IASLC Physician Survey: Topic: Radiation Oncology.
- Author
-
Gaspar, Laurie E., Mornex, Françoise, Kong, Feng-Ming (Spring), and Hirsch, Fred
- Published
- 2016
- Full Text
- View/download PDF
28. Triple modality (neoadjuvant chemoradiotherapy followed by surgical resection): is it better than definitive chemoradiation therapy in cancer of the thoracic esophagus?
- Author
-
Schefter, Tracey E. and Gaspar, Laurie E.
- Subjects
- *
CLINICAL trials , *COMBINED modality therapy , *ESOPHAGOSCOPY , *ESOPHAGEAL tumors , *LONGITUDINAL method , *RADIOTHERAPY , *TUMOR classification , *TREATMENT effectiveness ,DIGESTIVE organ surgery - Published
- 2002
- Full Text
- View/download PDF
29. Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology.
- Author
-
Kong, Feng-Ming (Spring), Cuneo, Kyle C., Wang, Li, Bonner, James A., Gaspar, Laurie E., Komaki, Ritsuko, Sun, Alexander, Morris, David E., Sandler, Howard M., and Movsas, Benjamin
- Abstract
Abstract: Purpose: To better define patterns of practice for patients with non-small cell lung cancer (NSCLC) in the United States. Methods and Materials: A survey of 36 questions was designed to collect information regarding practice patterns of radiation oncologists for the management of patients with NSCLC. All American Society for Radiation Oncology members were invited to respond. Results: Four hundred twenty-four responses from radiation oncologists in the United States were received. The response rate for the survey was approximately 20%. Substantial discrepancies were seen in the use of stereotactic body radiation therapy (SBRT) for patients with peripherally and centrally located early-stage tumors and in the recommended SBRT dose. There was a near consensus opinion regarding the use of concurrent chemotherapy and the radiation dose for patients with inoperable stage II and III NSCLC with a good performance status; however, in patients with a poor performance status or in patients with stage IV disease treatment recommendations differed remarkably. Additionally, the use of elective nodal irradiation and the assessment of tumor motion during simulation were highly variable. Thoracic radiation oncologists were more likely to prescribe higher doses, omit elective nodal irradiation, and use advanced technologies (P < .001). Conclusions: Substantial variations were seen in the management of patients with stage I and IV NSCLC in addition to the incorporation of new technology. This information can be used to help design meaningful clinical trials. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
30. Resident-Reported Brachytherapy Experience in ACGME-Accredited Radiation Oncology Training Programs
- Author
-
Lee, W. Robert, Gaspar, Laurie E., Shrieve, Dennis, Wilson, Lynn D., Griem, Katherine L., Compton, Julia, and Amdur, Robert J.
- Published
- 2013
- Full Text
- View/download PDF
31. Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy.
- Author
-
Vinogradskiy, Yevgeniy, Castillo, Richard, Castillo, Edward, Schubert, Leah, Jones, Bernard L., Faught, Austin, Gaspar, Laurie E., Kwak, Jennifer, Bowles, Daniel W., Waxweiler, Timothy, Dougherty, Jingjing M., Gao, Dexiang, Stevens, Craig, Miften, Moyed, Kavanagh, Brian, Grills, Inga, Rusthoven, Chad G., and Guerrero, Thomas
- Subjects
- *
RADIOTHERAPY , *RADIATION pneumonitis , *CANCER treatment , *CLINICAL trials , *COMPUTED tomography - Abstract
Purpose: Radiation pneumonitis remains a major limitation in the radiation therapy treatment of patients with lung cancer. Functional avoidance radiation therapy uses functional imaging to reduce pulmonary toxic effects by designing radiation therapy plans that reduce doses to functional regions of the lung. Lung functional imaging has been developed that uses 4-dimensional computed tomography (4DCT) imaging to calculate 4DCT-based lung ventilation (4DCT-ventilation). A phase 2 multicenter study was initiated to evaluate 4DCT-ventilation functional avoidance radiation therapy. The study hypothesis was that functional avoidance radiation therapy could reduce the rate of grade ≥2 radiation pneumonitis to 12% compared with a 25% historical rate, with the trial being positive if ≤16.4% of patients experienced grade ≥2 pneumonitis.Methods and Materials: Lung cancer patients receiving curative-intent radiation therapy (prescription doses of 45-75 Gy) and chemotherapy were accrued. Patient 4DCT scans were used to generate 4DCT-ventilation images. The 4DCT-ventilation images were used to generate functional avoidance plans that reduced doses to functional portions of the lung while delivering the prescribed tumor dose. Pneumonitis was evaluated by a clinician at 3, 6, and 12 months after radiation therapy.Results: Sixty-seven evaluable patients were accrued between April 2015 and December 2019. The median prescription dose was 60 Gy (range, 45-66 Gy) delivered in 30 fractions (range, 15-33 fractions). The average reduction in the functional volume of lung receiving ≥20 Gy with functional avoidance was 3.5% (range, 0%-12.8%). The median follow-up was 312 days. The rate of grade ≥2 radiation pneumonitis was 10 of 67 patients (14.9%; 95% upper CI, 24.0%), meeting the phase 2 criteria.Conclusions: 4DCT-ventilation offers an imaging modality that is convenient and provides functional imaging without an extra procedure necessary. This first report of a multicenter study of 4DCT-ventilation functional avoidance radiation therapy provided data showing that the trial met phase 2 criteria and that evaluation in a phase 3 study is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
32. Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
- Author
-
Reddy, Krishna, Damek, Denise, Gaspar, Laurie E., Ney, Douglas, Waziri, Allen, Lillehei, Kevin, Stuhr, Kelly, Kavanagh, Brian D., and Chen, Changhu
- Subjects
- *
GLIOBLASTOMA multiforme , *GLIOBLASTOMA multiforme treatment , *PHYSIOLOGICAL effects of radiation , *CLINICAL trials , *SURVIVAL analysis (Biometry) , *RADIOTHERAPY , *CANCER radiotherapy , *SURGICAL excision , *DIAGNOSIS - Abstract
Purpose: To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ). Methods and Materials: Patients with newly diagnosed GBM after biopsy or resection and with adequate performance status and organ or bone marrow function were eligible for this study. Patients received postoperative hypo-IMRT to the surgical cavity and residual tumor seen on T1-weighted brain MRI with a 5-mm margin to a total dose of 60 Gy in 10 fractions (6 Gy/fraction) and to the T2 abnormality on T2-weighted MRI with 5-mm margin to 30 Gy in 10 fractions (3 Gy/fraction). Concurrent TMZ was given at 75 mg/m2/day for 28 consecutive days. Adjuvant TMZ was given at 150 to 200 mg/m2/day for 5 days every 28 days. Toxicities were defined using Common Terminology Criteria for Adverse Events version 3.0. Results: Twenty-four patients were treated, consisting of 14 men, 10 women; a median age of 60.5 years old (range, 27–77 years); and a median Karnofsky performance score of 80 (range, 60–90). All patients received hypo-IMRT and concurrent TMZ according to protocol, except for 2 patients who received only 14 days of concurrent TMZ. The median number of adjuvant TMZ cycles was 6.5 (range, 0–14).With a median follow-up of 14.8 months (range, 2.7–34.2 months) for all patients and a minimum follow-up of 20.6 months for living patients, no instances of grade 3 or higher nonhematologic toxicity were observed. The median OS was 16.6 months (range, 4.1–35.9 months). Six patients underwent repeated surgery for suspected tumor recurrence; necrosis was found in 50% to 100% of the resected specimens. Conclusion: In selected GBM patients, 60 Gy hypo-IMRT delivered in 6-Gy fractions over 2 weeks with concurrent and adjuvant TMZ is safe. OS in this small cohort of patients was comparable to that treated with current standard of care therapy. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
33. Phase I Dose Escalation Trial of Vandetanib With Fractionated Radiosurgery in Patients With Recurrent Malignant Gliomas
- Author
-
Fields, Emma C., Damek, Denise, Gaspar, Laurie E., Liu, Arthur K., Kavanagh, Brian D., Waziri, Allen, Lillehei, Kevin, and Chen, Changhu
- Subjects
- *
GLIOMA treatment , *RADIOSURGERY , *CANCER relapse , *DRUG dosage , *STEREOTAXIC techniques , *ASTROCYTOMAS , *MEDICAL statistics - Abstract
Purpose: To determine the maximum tolerated dose (MTD) of vandetanib with fractionated stereotactic radiosurgery (SRS) in patients with recurrent malignant gliomas. Methods and Materials: Patients with a recurrent malignant glioma and T1-enhancing recurrent tumor ≤6 cm were eligible. Vandetanib was given orally, once per day, 7 days a week, starting at least 7 days before SRS and continued until a dose-limiting toxicity (DLT) or disease progression. The planned vandetanib daily dose was 100 mg, 200 mg, and 300 mg for the cohorts 1, 2, and 3, respectively, and was escalated using a standard 3+3 design. A total SRS dose of 36 Gy, 12 Gy per fraction, was delivered over 3 consecutive days. The MTD was defined as the dose of vandetanib at which less than 33% of patients developed DLTs, defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 3 as any Grade 3 or greater nonhematologic toxicity and Grade 4 or greater hematologic toxicity. Results: Ten patients were treated, 6 on cohort 1 and 4 on cohort 2. Treatment characteristics were: 7 men, 3 women; median age, 40 years (range, 22–72); 7 GBM, 3 anaplastic astrocytoma (AA); median initial radiation (RT) dose, 60 Gy (range, 59.4–70); median interval since initial RT, 14.5 months (range, 7–123); All patients received SRS per protocol. The median follow-up time was 4 months (range, 1–10 months). Median time on vandetanib was 3 months (range 1–11). One of 6 patients in the first cohort developed a DLT of Grade 3 hemothorax while on anticoagulation. The MTD was reached when 2 of the 4 patients enrolled in the second cohort developed DLTs. Six patients had radiographic response, 2 with stable disease. Conclusion: The MTD of vandetanib, with SRS in recurrent malignant glioma, is 100 mg daily. Further evaluation of safety and efficacy is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- Author
-
Chen, Changhu, Damek, Denise, Gaspar, Laurie E., Waziri, Allen, Lillehei, Kevin, Kleinschmidt-DeMasters, B.K., Robischon, Monica, Stuhr, Kelly, Rusthoven, Kyle E., and Kavanagh, Brian D.
- Subjects
- *
GLIOBLASTOMA multiforme treatment , *CANCER radiotherapy , *CANCER chemotherapy , *PHYSIOLOGICAL effects of radiation , *SURVIVAL analysis (Biometry) , *CANCER invasiveness , *CLINICAL trials - Abstract
Purpose: To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme. Methods and Materials: Patients with newly diagnosed glioblastoma multiforme after biopsy or resection and with adequate performance status, bone marrow, and organ function were eligible. The patients underwent postoperative intensity-modulated radiotherapy (IMRT) with concurrent and adjuvant TMZ. All patients received a total dose of 60 Gy to the surgical cavity and residual tumor, with a 5-mm margin. IMRT biologic dose intensification was achieved by escalating from 3 Gy/fraction (Level 1) to 6 Gy/fraction (Level 4) in 1-Gy increments. Concurrent TMZ was given at 75 mg/m2/d for 28 consecutive days. Adjuvant TMZ was given at 150–200 mg/m2/d for 5 days every 28 days. Dose-limiting toxicity was defined as any Common Terminology Criteria for Adverse Events, version 3, Grade 3-4 nonhematologic toxicity, excluding Grade 3 fatigue, nausea, and vomiting. A standard 3+3 Phase I design was used. Results: A total of 16 patients were accrued (12 men and 4 women, median age, 69 years; range, 34–84. The median Karnofsky performance status was 80 (range, 60–90). Of the 16 patients, 3 each were treated at Levels 1 and 2, 4 at Level 3, and 6 at Level 4. All patients received IMRT and concurrent TMZ according to the protocol, except for 1 patient, who received 14 days of concurrent TMZ. The median number of adjuvant TMZ cycles was 7.5 (range, 0–12). The median survival was 16.2 months (range, 3–33). One patient experienced vision loss in the left eye 7 months after IMRT. Four patients underwent repeat surgery for suspected tumor recurrence 6–12 months after IMRT; 3 had radionecrosis. Conclusions: The maximal tolerated IMRT fraction size was not reached in our study. Our results have shown that 60 Gy IMRT delivered in 6-Gy fractions within 2 weeks with concurrent and adjuvant TMZ is tolerable in selected patients with a T1-weighted enhancing tumor <6 cm. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
35. Observation of a Dose–Control Relationship for Lung and Liver Tumors After Stereotactic Body Radiation Therapy
- Author
-
McCammon, Robert, Schefter, Tracey E., Gaspar, Laurie E., Zaemisch, Rebekah, Gravdahl, Daniel, and Kavanagh, Brian
- Subjects
- *
DOSE-response relationship in ionizing radiation , *TUMOR treatment , *LUNG tumors , *LIVER tumors , *CANCER radiotherapy , *METASTASIS , *RADIOSURGERY - Abstract
Purpose: To determine prognostic factors for local control of primary or metastatic tumors within the lung or liver treated with stereotactic body radiation therapy (SBRT) within a single institution. Methods and Materials: The records of 141 consecutive patients with 246 lesions treated with three-fraction SBRT from Oct 1999 through Aug 2005 were reviewed. Local control was assessed radiographically. Univariate and multivariate analyses were performed to evaluate the influence of the following factors on local control: total dose, expressed as either nominal prescription dose or equivalent uniform dose (EUD); gross tumor volume; primary site; treatment site (lung vs. other); histologic characteristics (adenocarcinoma vs. other); gender; age; and primary vs. metastatic tumor. Results: On univariate analysis, increased dose (either nominal or EUD) and smaller gross tumor volume were significant predictors of higher local control. Lesions treated to a nominal dose of 54 Gy or greater had a 3-year actuarial local control rate of 89.3% compared with 59.0% and 8.1% for those treated to 36–53.9 Gy and less than 36 Gy. On multivariate analysis, only increased nominal dose and EUD retained statistical significance. Treatment was well tolerated; 5.7% of patients experienced Grade 3 or higher toxicity. Conclusions: This large single-institution series suggests a dose–control relationship within the range of SBRT doses applied. Excellent local control rates are achieved with a nominal dose of 54 Gy or greater, corresponding to an EUD greater than 65.3 Gy. These results support the use of aggressive SBRT regimens when durable tumor control is the primary objective. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database
- Author
-
Sperduto, Paul W., Berkey, Brian, Gaspar, Laurie E., Mehta, Minesh, and Curran, Walter
- Subjects
- *
CANCER invasiveness , *METASTASIS , *RADIOTHERAPY , *NEUROSURGERY - Abstract
Purpose: The purpose of this study is to introduce a new prognostic index for patients with brain metastases and compare it with three published indices. Treatment for brain metastases varies widely. A sound prognostic index is thus important to guide both clinical decision making and outcomes research. Methods and Materials: A new index was developed because of limitations in the three existing indices and new data (Radiation Therapy Oncology Group 9508) are available since the others were developed. All four indices were compared using the Radiation Therapy Oncology Group database of 1,960 patients with brain metastases from five randomized trials. The ability of the four indices to distinguish its separate classes was determined statistically. Advantages and disadvantages of each index are discussed. Results: Recursive partitioning analysis (RPA) and the new Graded Prognostic Assessment (GPA) had the most statistically significant differences between classes (p < 0.001 for all classes). Conclusions: The new index, the GPA, is as prognostic as the RPA and more prognostic than the other indices. The GPA is the least subjective, most quantitative and easiest to use of the four indices. Future clinical trials should compare the GPA with the RPA to prospectively validate these findings. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
37. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care
- Author
-
Little, Alex G., Gay, E. Greer, Gaspar, Laurie E., and Stewart, Andrew K.
- Subjects
- *
CANCER treatment , *CANCER patients , *LUNG cancer , *CANCER hospitals - Abstract
Summary: Purpose: To determine the epidemiology, pathology and patterns of care for patients with non-small cell lung cancer (NSCLC) in the United States. Methods: In 2001 the National Cancer Data Base, under direction of the American College of Surgeons, conducted a patient care evaluation study in 719 hospitals. We collected information on patient demographics and histories, diagnostic and staging methods, pathology, and initial treatment. Results: Information on 40,909 patients was obtained; 93% were smokers. Slightly more than half were older than 70 years; 58.5% were male and 35% had adenocarcinoma. Comorbid conditions were present in 71.8% and 22% had a prior malignancy. A chest CT scan was performed in 92% of patients and PET scans in 19.3%. Mediastinoscopy was performed in 20.3%. 67.2% of patients had Stage III or IV disease. More of the Hispanic, Asian or Black patients than White had Stage IV disease (p <0.01). Treatment was multimodality in a little over 30% of patients. Surgery alone was primarily utilized for patients in Stage I or II. Choice of treatment correlated more with stage and age than comorbidities. Conclusion: Our results substantiated the pattern of increasing proportions of women with NSCLC and the increasing frequency of adenocarcinoma. Most patients presented with Stage III or IV disease. Ethnic minorities were more likely to present in late stage disease than Whites. Treatment strategies depended more on stage and age than comorbid burden. Older patients were less likely to receive surgery and more likely to be treated with radiation only or have no treatment. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
38. Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?
- Author
-
Nieder, Carsten, Mehta, Minesh P., Guckenberger, Matthias, Gaspar, Laurie E., Rusthoven, Chad G., Sahgal, Arjun, Grosu, Anca L., and De Ruysscher, Dirk
- Subjects
- *
BRAIN metastasis , *SURVIVAL analysis (Biometry) , *PREDICTION models , *PROGNOSTIC models , *MEDICAL personnel , *BRAIN diseases - Abstract
• Survival prediction models are still evolving and imperfect. • Some components of these models carry the risk of inter-observer inconsistency and time-dependent variation. • Opportunities exist to enhance the assessment of extracranial metastases and potential surrogates. Survival prediction models may serve as decision-support tools for clinicians who have to assign the right treatment to each patient, in a manner whereby harmful over- or undertreatment is avoided as much as possible. Current models differ regarding their components, the overall number of components and the weighting of individual components. Some of the components are easy to assess, such as age or primary tumor type. Others carry the risk of inter-assessor inconsistency and time-dependent variation. The present publication focuses on issues related to assessment of extracranial metastases and potential surrogates, e.g. blood biomarkers. It identifies areas of controversy and provides recommendations for future research projects, which may contribute to prognostic models with improved accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
- Author
-
Bogart, Jeffrey A., Wang, Xiaofei, Masters, Gregory A., Gao, Junheng, Komaki, Ritsuko, Gaspar, Laurie E., Heymach, John V., Dobelbower, Michael Christian, Kuzma, Charles, Stinchcombe, Thomas E., and Vokes, Everett E.
- Subjects
- *
SMALL cell lung cancer , *PATIENTS' attitudes - Abstract
• CALGB 30610/RTOG 0538 used a novel design in order to select one of two high dose radiotherapy regimens to compare against standard 45 Gy BID in LSCLC. • The experimental regimen, either 70 Gy once-daily (QD) and 61.2 Gy concomitant boost (CB), would be chosen based on interim toxicity and tolerability. • Both experimental regimens appeared tolerable and had similar toxicity scores. • The decision to discontinue the 61.2 Gy CB arm was based on the observation that more patients experience grade 4 pulmonary toxicity with this regimen. It was also believed that studying 70 Gy QD would have the larger potential impact on clinical practice. • Suggestions for improvement in similar trial designs are discussed. • Long-term outcomes of the study will provide further data regarding the therapeutic ratio of high dose QD radiotherapy in LSCLC. The CALGB 30610/RTOG 0538 randomized trial was designed to test whether high-dose thoracic radiotherapy (TRT) would improve survival compared with 45 Gy twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC). Two piloted experimental TRT regimens were of interest to study, 70 Gy daily (QD) and 61.2 Gy concomitant boost (CB). Driven by concerns about adequate patient accrual, a study design was employed that eliminated one experimental TRT arm based on early interim toxicity and tolerability, with the study then continuing as a traditional 2-arm phase III study. Patients with LSCLC were assigned to receive four cycles of cisplatin and etoposide chemotherapy with one of 3 TRT regimens starting with either the first or second cycle of chemotherapy. The interim endpoint was the cumulative highest toxicity calculated from a scoring system based on treatment-related grade 3 and higher toxicity and the ability to complete therapy in the experimental arms. The final interim analysis was performed after 70 patients accrued to each experimental cohort, and a difference in treatment related toxicity scoring was not found (p = 0.739). Severe esophageal toxicity was comparable in both cohorts. Pulmonary toxicity was low overall, though 4 patients (5.7 %) on the 61.2 Gy arm developed grade 4 dyspnea, which was not observed in the 70 Gy arm. A protocol mandated decision was made to discontinue the 61.2 Gy arm following review of toxicity with the Data and Safety Monitoring Board. A randomized trial design using a planned early interim toxicity analysis to discriminate between experimental treatment arms is feasible in a phase III setting. Refinement of the design could increase the likelihood of detecting clinically meaningful differences in toxicity in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer.
- Author
-
Vinogradskiy, Yevgeniy, Diot, Quentin, Jones, Bernard, Castillo, Richard, Castillo, Edward, Kwak, Jennifer, Bowles, Daniel, Grills, Inga, Myziuk, Nicholas, Guerrero, Thomas, Stevens, Craig, Schefter, Tracey, Gaspar, Laurie E., Kavanagh, Brian, Miften, Moyed, and Rusthoven, Chad
- Subjects
- *
POSITRON emission , *CARDIAC imaging , *LUNG cancer , *POSITRON emission tomography , *HEART metabolism , *TREATMENT of lung tumors , *HEART , *LUNG tumors , *SURVIVAL analysis (Biometry) , *RESEARCH funding - Abstract
Purpose: Studies have noted a link between radiation dose to the heart and overall survival (OS) for patients with lung cancer treated with chemoradiation. The purpose of this study was to characterize pre- to posttreatment cardiac metabolic changes using fluorodeoxyglucose/positron emission tomography (FDG-PET) images and to evaluate whether changes in cardiac metabolism predict for OS.Methods and Materials: Thirty-nine patients enrolled in a functional avoidance prospective study who had undergone pre- and postchemoradiation FDG-PET imaging were evaluated. For each patient, the pretreatment and posttreatment PET/CTs were rigidly registered to the planning CT, dose, and structure set. PET-based metabolic dose-response was assessed by comparing pretreatment to posttreatment mean standardized uptake values (SUVmean) in the heart as a function of dose-bin. OS analysis was performed by comparing SUVmean changes for patients who were alive or had died at last follow-up and by using a multivariate model to assess whether pre- to posttreatment SUVmean changes were a predictor of OS.Results: The dose-response curve revealed increasing changes in SUV as a function of cardiac dose with an average SUVmean increase of 1.7% per 10 Gy. Patients were followed for a median of 437 days (range, 201-1131 days). SUVmean change was significantly predictive of OS on multivariate analysis with a hazard ratio of 0.541 (95% confidence intervals, 0.312-0.937). Patients alive at follow-up had an average increase of 17.2% in cardiac SUVmean while patients that died had an average decrease in SUVmean decrease of 13.5% (P = .048).Conclusions: Our data demonstrated that posttreatment SUV changes in the heart were significant indicators of dose-response and predictors of OS. The present work is hypothesis generating and must be validated in an independent cohort. If validated, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
41. Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy.
- Author
-
Vinogradskiy, Yevgeniy, Rusthoven, Chad G, Schubert, Leah, Jones, Bernard, Faught, Austin, Castillo, Richard, Castillo, Edward, Gaspar, Laurie E, Kwak, Jennifer, Waxweiler, Timothy, Dougherty, Michele, Gao, Dexiang, Stevens, Craig, Miften, Moyed, Kavanagh, Brian, Guerrero, Thomas, and Grills, Inga
- Subjects
- *
CLINICAL trials , *COMPARATIVE studies , *COMPUTED tomography , *EXPERIMENTAL design , *LONGITUDINAL method , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *COMPUTERS in medicine , *RADIATION doses , *RADIOTHERAPY , *RESEARCH , *RESEARCH funding , *RESPIRATION , *EVALUATION research , *RADIATION pneumonitis - Abstract
Purpose: Functional imaging has been proposed that uses 4DCT images to calculate 4DCT-based lung ventilation (4DCT-ventilation). We have started a 2-institution, phase 2 prospective trial evaluating the feasibility, safety, and preliminary efficacy of 4DCT-ventilation functional avoidance. The trial hypothesis is that the rate of grade ≥2 radiation pneumonitis could be reduced to 12% with functional avoidance, compared with a 25% rate of pneumonitis with a historical control. The trial employed a Simon 2-stage design with a planned futility analysis after 17 evaluable patients. The purpose of this work is to present the trial design and implementation, dosimetric data, and clinical results for the planned futility analysis.Methods and Materials: Eligible patients were patients with lung cancer who were prescribed doses of 45 to 75 Gy. For each patient, the 4DCT data were used to generate a 4DCT-ventilation image using the Hounsfield unit technique along with a compressible flow-based image registration algorithm. Two intensity modulated radiation therapy treatment plans were generated: (1) a standard lung plan and (2) a functional avoidance treatment plan that aimed to reduce dose to functional lung while meeting target and normal tissue constraints. Patients were treated with the functional avoidance plan and evaluated for thoracic toxicity (presented as rate and 95% confidence intervals [CI]) with a 1-year follow-up.Results: The V20 to functional lung was 21.6% ± 9.5% (mean ± standard deviation) with functional avoidance, representing a decrease of 3.2% (P < .01) relative to standard, nonfunctional treatment plans. The rates of grade ≥2 and grade ≥3 radiation pneumonitis were 17.6% (95% CI, 3.8%-43.4%) and 5.9% (95% CI, 0.1%-28.7%), respectively.Conclusions: Dosimetrically, functional avoidance achieved reduction in doses to functional lung while meeting target and organ at risk constraints. On the basis of Simon's 2-stage design and the 17.6% grade ≥2 pneumonitis rate, the trial met its futility criteria and has continued accrual. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
42. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
- Author
-
Alexander, Brian M, Brown, Paul D, Ahluwalia, Manmeet S, Aoyama, Hidefumi, Baumert, Brigitta G, Chang, Susan M, Gaspar, Laurie E, Kalkanis, Steven N, Macdonald, David R, Mehta, Minesh P, Soffietti, Riccardo, Suh, John H, van den Bent, Martin J, Vogelbaum, Michael A, Wefel, Jeffrey S, Lee, Eudocia Q, Wen, Patrick Y, and Response Assessment in Neuro-Oncology (RANO) group
- Abstract
The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we highlight issues related to, and provide recommendations for, the design of clinical trials on local therapies for CNS metastases from solid tumours. We discuss endpoint selection criteria, the analysis appropriate for early-phase and late-phase trials, the association between tumour-specific and clinically meaningful endpoints, and possible issues related to the estimation of local control in the context of competing risks. In light of these discussions, we make specific recommendations on the clinical trial design of local therapies for brain metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
MELANOMA prognosis , *MELANOMA diagnosis , *BRAIN metastasis , *BIOMARKERS , *RETROSPECTIVE studies , *AGE distribution , *BRAIN tumors , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MELANOMA , *PROGNOSIS , *REGRESSION analysis , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *GENETIC markers , *EVALUATION research , *KARNOFSKY Performance Status - Abstract
Purpose: To update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a markedly heterogeneous patient population, patients with melanoma and brain metastases, using a larger, more current cohort, including molecular markers.Methods: The original Melanoma-GPA is based on data from 483 patients whose conditions were diagnosed between 1985 and 2005. This is a multi-institutional retrospective database analysis of 823 melanoma patients with newly diagnosed brain metastases from January 1, 2006, to December 31, 2015. Multivariable analyses identified significant prognostic factors, which were weighted and included in the updated index (Melanoma-molGPA). Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios to design the updated Melanoma-molGPA in which scores of 4.0 and 0.0 are associated with the best and worst prognoses, as with all of the diagnosis-specific GPA indices. Log-rank tests were used to compare adjacent classes.Results: There were 5 significant prognostic factors for survival (age, Karnofsky performance status [KPS], extracranial metastases [ECM], number of brain metastases, and BRAF status), whereas only KPS and the number of brain metastases were significant in the original Melanoma-GPA. Median survival improved from 6.7 to 9.8 months between the 2 treatment eras, and the median survival times for patients with Melanoma-molGPA of 0 to 1.0, 1.5 to 2.0, 2.5 to 3.0, and 3.5 to 4.0 were 4.9, 8.3, 15.8, and 34.1 months (P<.0001 between each adjacent group).Conclusions: Survival and our ability to estimate survival in melanoma patients with brain metastases has improved significantly. The updated Melanoma-molGPA, a user-friendly tool to estimate survival, will facilitate clinical decision making regarding whether and which treatment is appropriate and will also be useful for stratification of future clinical trials. To further simplify use, a free online/smart phone app is available at brainmetgpa.com. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
44. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
CANCER treatment , *METASTASIS , *TREATMENT of brain cancer , *BRAIN cancer patients , *MELANOMA treatment , *PATIENTS - Abstract
Purpose: Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients.Methods and Materials: We created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005).Results: BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months. MS for BRAF-positive and BRAF-negative patients was 13 months and 9 months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7 months and 10.0 months, respectively (P<.01). Reflecting treatment-trend changes, use of whole-brain radiation therapy decreased from 48% to 26% during this period. Among BRAF-positive patients, 71% received targeted BRAF and/or MEK inhibitors and 57% received some combination of targeted therapy, chemotherapy, and/or immunotherapy.Conclusions: For melanoma patients with brain metastases, BRAF-positive patients survive longer than BRAF-negative patients and overall survival has improved from 1985-2005 to 2006-2015. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
- Author
-
Gomez, Daniel R, JrBlumenschein, George R, Lee, J Jack, Hernandez, Mike, Ye, Rong, Camidge, D Ross, Doebele, Robert C, Skoulidis, Ferdinandos, Gaspar, Laurie E, Gibbons, Don L, Karam, Jose A, Kavanagh, Brian D, Tang, Chad, Komaki, Ritsuko, Louie, Alexander V, Palma, David A, Tsao, Anne S, Sepesi, Boris, William, William N, and Zhang, Jianjun
- Subjects
- *
CANCER treatment , *NON-small-cell lung carcinoma , *CANCER invasiveness , *CANCER chemotherapy , *PROGRESSION-free survival , *EPIDERMAL growth factor receptors , *CLINICAL trials , *COMPARATIVE studies , *LUNG cancer , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *RESEARCH , *RESEARCH funding , *EVALUATION research , *RANDOMIZED controlled trials - Abstract
Background: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative therapy for patients with oligometastatic NSCLC is unknown. We aimed to assess the effect of local consolidative therapy on progression-free survival.Methods: In this multicentre, randomised, controlled, phase 2 study, eligible patients from three hospitals had histological confirmation of stage IV NSCLC, three or fewer metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group performance status score of 2 or less, had received standard first-line systemic therapy, and had no disease progression before randomisation. First-line therapy was four or more cycles of platinum doublet therapy or 3 or more months of EGFR or ALK inhibitors for patients with EGFR mutations or ALK rearrangements, respectively. Patients were randomly assigned (1:1) to either local consolidative therapy ([chemo]radiotherapy or resection of all lesions) with or without subsequent maintenance treatment or to maintenance treatment alone, which could be observation only. Maintenance treatment was recommended based on a list of approved regimens, and observation was defined as close surveillance without cytotoxic treatment. Randomisation was not masked and was balanced dynamically on five factors: number of metastases, response to initial therapy, CNS metastases, intrathoracic nodal status, and EGFR and ALK status. The primary endpoint was progression-free survival analysed in all patients who were treated and had at least one post-baseline imaging assessment. The study is ongoing but not recruiting participants. This study is registered with ClinicalTrials.gov, number NCT01725165.Findings: Between Nov 28, 2012, and Jan 19, 2016, 74 patients were enrolled either during or at the completion of first-line systemic therapy. The study was terminated early after randomisation of 49 patients (25 in the local consolidative therapy group and 24 in the maintenance treatment group) as part of the annual analyses done by the Data Safety Monitoring Committee of all randomised trials at MD Anderson Cancer Center, and before a planned interim analysis of 44 events. At a median follow-up time for all randomised patients of 12·39 months (IQR 5·52-20·30), the median progression-free survival in the local consolidative therapy group was 11·9 months (90% CI 5·7-20·9) versus 3·9 months (2·3-6·6) in the maintenance treatment group (hazard ratio 0·35 [90% CI 0·18-0·66], log-rank p=0·0054). Adverse events were similar between groups, with no grade 4 adverse events or deaths due to treatment. Grade 3 adverse events in the maintenance therapy group were fatigue (n=1) and anaemia (n=1) and in the local consolidative therapy group were oesophagitis (n=2), anaemia (n=1), pneumothorax (n=1), and abdominal pain (n=1, unlikely related).Interpretation: Local consolidative therapy with or without maintenance therapy for patients with three or fewer metastases from NSCLC that did not progress after initial systemic therapy improved progression-free survival compared with maintenance therapy alone. These findings suggest that aggressive local therapy should be further explored in phase 3 trials as a standard treatment option in this clinical scenario.Funding: MD Anderson Lung Cancer Priority Fund, MD Anderson Cancer Center Moon Shot Initiative, and Cancer Center Support (Core), National Cancer Institute, National Institutes of Health. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
46. In Reply to Drs. Weltman and Brandt
- Author
-
Sperduto, Paul W., Berkey, Brian, Gaspar, Laurie E., Mehta, Minesh, and Curran, Walter
- Published
- 2008
- Full Text
- View/download PDF
47. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.
- Author
-
Sperduto, Paul W., Yang, T. Jonathan, Beal, Kathryn, Pan, Hubert, Brown, Paul D., Bangdiwala, Ananta, Shanley, Ryan, Yeh, Norman, Gaspar, Laurie E., Braunstein, Steve, Sneed, Penny, Boyle, John, Kirkpatrick, John P., Mak, Kimberley S., Shih, Helen A., Engelman, Alex, Roberge, David, Arvold, Nils D., Alexander, Brian, and Awad, Mark M.
- Subjects
- *
PROTEIN-tyrosine kinases , *PROTEIN kinases , *ADENOCARCINOMA , *CANCER treatment , *METASTASIS , *PATIENTS - Abstract
Purpose: Lung cancer remains the most common cause of both cancer mortality and brain metastases (BM). The purpose of this study was to assess the effect of gene alterations and tyrosine kinase inhibition (TKI) on median survival (MS) and cause of death (CoD) in patients with BM from lung adenocarcinoma (L-adeno).Methods: A multi-institutional retrospective database of patients with L-adeno and newly diagnosed BM between 2006 and 2014 was created. Demographics, gene alterations, treatment, MS, and CoD were analyzed. The treatment patterns and outcomes were compared with those in prior trials.Results: Of 1521 L-adeno patients, 816 (54%) had known alteration status. The gene alteration rates were 29%, 10%, and 26% for EGFR, ALK, and KRAS, respectively. The time from primary diagnosis to BM for EGFR-/+ was 10/15 months (P=.02) and for ALK-/+ was 10/20 months (P<.01), respectively. The MS for the group overall (n=1521) was 15 months. The MS from first treatment for BM for EGFR and ALK-, EGFR+, ALK+ were 14, 23 (P<.01), and 45 (P<.0001) months, respectively. The MS after BM for EGFR+ patients who did/did not receive TKI before BM was 17/30 months (P<.01), respectively, but the risk of death was not statistically different between TKI-naïve patients who did/did not receive TKI after the diagnosis of BM (EGFR/ALK hazard ratios: 1.06 [P=.84]/1.60 [P=.45], respectively). The CoD was nonneurologic in 82% of patients with known CoD.Conclusion: EGFR and ALK gene alterations are associated with delayed onset of BM and longer MS relative to patients without these alterations. The CoD was overwhelmingly nonneurologic in patients with known CoD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
48. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
- Author
-
Robin, Tyler P., Jones, Bernard L., Amini, Arya, Koshy, Matthew, Gaspar, Laurie E., Liu, Arthur K., Nath, Sameer K., Kavanagh, Brian D., Camidge, D. Ross, and Rusthoven, Chad G.
- Subjects
- *
SMALL cell lung cancer , *CANCER treatment , *STEREOTACTIC radiosurgery , *BRAIN metastasis , *HISTOLOGY , *DIAGNOSIS - Abstract
Introduction Whole-brain radiation therapy (WBRT) is the standard approach for brain metastases (BM) arising in patients with small-cell lung cancer (SCLC), but the neurocognitive toxicities of WBRT are well documented. For this reason, stereotactic radiosurgery (SRS) alone is the preferred modality for limited BM in most histologies, but in SCLC there are few data exploring this approach. Methods We queried the National Cancer Database (NCDB) for patients with SCLC with BM at diagnosis and stratified by upfront SRS compared with upfront WBRT ± SRS. We utilized multivariate Cox regression and propensity score matching (PSM) to determine the impact on overall survival (OS) of each approach. Results 5952 eligible patients (WBRT: 5752; SRS: 200) were identified from 2010 to 2014 with a median follow-up of 40.0 months. Upfront SRS was associated with superior OS (median 10.8 vs 7.1 months, HR 0.65, 95% CI 0.55–0.75, p < 0.001), which persisted on multivariate analysis controlling for comorbidities, extracranial metastases, age, race/ethnicity, and gender (HR 0.70, 95% CI 0.60–0.81, p < 0.001). These results were confirmed in PSM analysis. A subset analysis comparing outcomes after SRS vs SRS + WBRT showed no differences in OS (p = .601). Conclusions To our knowledge, this is the largest dataset of patients treated with SRS alone for SCLC. The observation of favorable OS with SRS alone in this contemporary dataset suggests that SRS alone may be appropriate for some patients with SCLC. Prospective investigations of SRS in SCLC are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
49. Clinical Validation of 4-Dimensional Computed Tomography Ventilation With Pulmonary Function Test Data.
- Author
-
Brennan, Douglas, Schubert, Leah, Diot, Quentin, Castillo, Richard, Castillo, Edward, Guerrero, Thomas, Martel, Mary K., Linderman, Derek, Gaspar, Laurie E., Miften, Moyed, Kavanagh, Brian D., and Vinogradskiy, Yevgeniy
- Subjects
- *
LUNG cancer diagnosis , *OBSTRUCTIVE lung diseases , *VENTILATION equipment , *COMPUTED tomography , *DISEASE mapping , *RADIATION dosimetry - Abstract
Purpose A new form of functional imaging has been proposed in the form of 4-dimensional computed tomography (4DCT) ventilation. Because 4DCTs are acquired as part of routine care for lung cancer patients, calculating ventilation maps from 4DCTs provides spatial lung function information without added dosimetric or monetary cost to the patient. Before 4DCT-ventilation is implemented it needs to be clinically validated. Pulmonary function tests (PFTs) provide a clinically established way of evaluating lung function. The purpose of our work was to perform a clinical validation by comparing 4DCT-ventilation metrics with PFT data. Methods and Materials Ninety-eight lung cancer patients with pretreatment 4DCT and PFT data were included in the study. Pulmonary function test metrics used to diagnose obstructive lung disease were recorded: forced expiratory volume in 1 second (FEV1) and FEV1/forced vital capacity. Four-dimensional CT data sets and spatial registration were used to compute 4DCT-ventilation images using a density change–based and a Jacobian-based model. The ventilation maps were reduced to single metrics intended to reflect the degree of ventilation obstruction. Specifically, we computed the coefficient of variation (SD/mean), ventilation V20 (volume of lung ≤20% ventilation), and correlated the ventilation metrics with PFT data. Regression analysis was used to determine whether 4DCT ventilation data could predict for normal versus abnormal lung function using PFT thresholds. Results Correlation coefficients comparing 4DCT-ventilation with PFT data ranged from 0.63 to 0.72, with the best agreement between FEV1 and coefficient of variation. Four-dimensional CT ventilation metrics were able to significantly delineate between clinically normal versus abnormal PFT results. Conclusions Validation of 4DCT ventilation with clinically relevant metrics is essential. We demonstrate good global agreement between PFTs and 4DCT-ventilation, indicating that 4DCT-ventilation provides a reliable assessment of lung function. Four-dimensional CT ventilation enables exciting opportunities to assess lung function and create functional avoidance radiation therapy plans. The present work provides supporting evidence for the integration of 4DCT-ventilation into clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. The Impact of Adjuvant Radiation Therapy for High-Grade Gliomas by Histology in the United States Population.
- Author
-
Rusthoven, Chad G., Carlson, Julie A., Waxweiler, Timothy V., Dally, Miranda J., Barón, Anna E., Yeh, Norman, Gaspar, Laurie E., Liu, Arthur K., Ney, Douglas E., Damek, Denise M., Lillehei, Kevin O., and Kavanagh, Brian D.
- Subjects
- *
RADIOTHERAPY , *HISTOLOGY , *GLIOBLASTOMA multiforme treatment , *ASTROCYTOMAS , *EPIDEMIOLOGY , *MEDICAL databases - Abstract
Purpose To compare the survival impact of adjuvant external beam radiation therapy (RT) for malignant gliomas of glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and mixed anaplastic oligoastrocytoma (AOA) histology. Methods and Materials The Surveillance, Epidemiology, and End Results (SEER) database was queried from 1998 to 2007 for patients aged ≥18 years with high-grade gliomas managed with upfront surgical resection, treated with and without adjuvant RT. Results The primary analysis totaled 14,461 patients, with 12,115 cases of GBM (83.8%), 1312 AA (9.1%), 718 AO (4.9%), and 316 AOA (2.2%). On univariate analyses, adjuvant RT was associated with significantly improved overall survival (OS) for GBMs (2-year OS, 17% vs 7%, p<.001), AAs (5-year OS, 38% vs 24%, p<.001), and AOAs (5-year OS, 55% vs 44%, p=.026). No significant differences in OS were observed for AOs (5-year OS, with RT 50% vs 56% without RT, p=.277). In multivariate Cox proportional hazards models accounting for extent of resection, age, sex, race, year, marital status, and tumor registry, RT was associated with significantly improved OS for both GBMs (HR, 0.52; 95% CI, 0.50-0.55; P <.001) and AAs (HR, 0.57; 95% CI, 0.48-0.68; P <.001) but only a trend toward improved OS for AOAs (HR, 0.70; 95% CI, 0.45-1.09; P =.110). Due to the observation of nonproportional hazards, Cox regressions were not performed for AOs. A significant interaction was observed between the survival impact of RT and histology overall (interaction P<.001) and in a model limited to the anaplastic (WHO grade 3) histologies. (interaction P=.024), characterizing histology as a significant predictive factor for the impact of RT. Subgroup analyses demonstrated greater hazard reductions with RT among patients older than median age for both GBMs and AAs (all interaction P≤.001). No significant interactions were observed between RT and extent of resection. Identical patterns of significance were observed for cause-specific survival and OS across analyses. Conclusions In this large population-based cohort, glioma histology represented a significant predictor for the survival impact of RT. Adjuvant RT was associated with improved survival for AAs, with benefits comparable to those observed for GBMs over the same 10-year interval. No survival advantage was observed with adjuvant RT for AOs. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.